The long-term effects of a number of flavonoids (such as apigenin, luteolin and amentoflavone) and vinpocetine on the neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE) were investigated. It was shown that apigenin, luteolin and vinpocetin are able to induce the activity of both NEP and ACE associated with the inhibition of the proliferation of the neuroblastoma cell line SK-N-SH. Amentoflavone has no effect on either NEP or ACE activity. An additional enhancement of cellular NEP activity could be detected after the treatment of the cells with a combination of both arabinosylcytosine and either apigenin or luteolin. This effect supports the assumption that apigenin and luteolin influence directly the gene expression of NEP. Taking into account the significant role of NEP and ACE in the degradation of amyloid beta peptides, the induction of both enzymes by long-term treatment with apigenin, luteolin and vinpocetine may have a beneficial effect regarding the prevention of the formation of amyloid plaques and the effect of these substances may be discussed as neuroprotective.
Neutral endopeptidase (EC 3.4.24.11, NEP), also known as neprilysin, and angiotenin-converting enzyme (EC 3.4.15.1, ACE) are zinc-endopeptidase enzymes acting as ectoenzymes on the outer surface of different cells and included in the metabolism of regulatory peptides, like substance P, bradykinin, enkephalins, natriuretic peptides and other vasoactive hormonal peptides [1] . Abnormal production and accumulation in the CNS of beta amyloid (Aβ) protein, a proteolytic product of amyloid-precursorprotein (APP) metabolism, is currently being investigated as one of the central mechanisms involved in the pathogenesis of Alzheimer's disease (AD). A shift in the balance between Aβ production and degradation might be responsible for the disease [2] . Therefore, activation of mechanisms that lower brain Aβ levels is considered valuable for the treatment of Alzheimer's disease. Neprilysin was found to be one of the major Aβ-degrading enzymes and a malfunction of this enzyme has been postulated in the etiology of AD [3] . Up-regulation of NEP in the brain prevents AD development by increasing β-amyloid (Aβ) clearance, resulting in a decrease of Aβ levels [4] . ACE has also been reported to play a role in Aβ degradation based on in-vitro and cellbased assays [5] . The recent studies on the reninangiotensin system (RAS) of the mammalian brain may explain the association between ACE and AD, which showed that angiotensin in astrocytes is required for the functional maintenance of the blood brain barrier [6] . Both angiotensin II and angiotensin 1V excite hippocampal neuronal activity [7] and regulate cerebral blood flow [8] . Various synthetic and naturally occurring compounds have been analyzed for their efficiency in the modulation of these pathological events. Examples of naturally occurring compounds achieving worldwide popularity for their therapeutic applications are flavonoids. Flavonoids are naturally occurring polyphenolic compounds with a wide distribution in the plant kingdom. Several effects of these plant flavonoids on life-style related diseases have been reported, including antioxidative [9] , anticancer [10] , anti-inflammatory [11] and antispasmodic activities [12] . Moreover, flavonoids have been reported to inhibit xanthine oxidase [13] , protein kinase C [14] , and phosphodiesterase [15] . We have previously shown that flavonoids from green tea extract, such as caffeine and theophylline, enhance the activity of the neuropeptidase NEP independently from the inhibition of cell proliferation [16] . For that, we have selected a further two flavonoids (apigenin and luteolin) to test their effect on NEP and ACE activity. Ginkgo biloba extract (EGb 761) can improve cognitive function in patients with dementia, including AD [17] . Amentoflavone is a flavonoidfraction component of EGb 761 [18] . Amentoflavone has been found to exhibit strong neuroprotection against cytotoxic insults induced by oxidative stress and amyloid β, suggesting their therapeutic potential against neurodegenerative diseases, including ischemic stroke and Alzheimer's disease [19] . Therefore, we selected it as a biflavonoid to test its effect on NEP and ACE activity. Vinpocetin is a synthetic ethyl ester of apovincamine, a vinca alkaloid obtained from the leaves of the lesser periwinkle plant, Vinca minor and discovered in the late1960s [20] . In Europe, vinpocetine was made available under the trade name Cavinton for the treatment of cerebrovascular-related pathologies [21] . It is able to enhance cerebral blood flow and cerebral metabolic rate [22] , as well as to reduce damage from free radicals by improving oxygen utilization [23] . For the beneficial effects of those substances in AD and other diseases, we have decided to test if apigenin, amentoflavone, luteolin and vinpocetine could also influence the activity of the specific cellular NEP and ACE after long-term treatment using the neuroblastoma cell line SK-N-SH to elucidate the beneficial effects and protective activities of these substances in AD, and to clarify the possible mechanism responsible for their pharmacological effectiveness.
Effects of apigenin, luteolin, amentoflavone and vinpocetin on the specific cellular NEP and ACE activity:
In the first series of experiments we tested the long-term effect (72 h of incubation) of apigenin, luteolin and vinpocetin (1-50 µM), and amentoflavone (1-20 µM), in respect to different concentrations, on the specific cellular NEP and ACE activity. We found that treatment of the SK-N-SH cells with apigenin, luteolin and vinpocetin (at concentration ≥ 10 µM) induced significantly the activity of the specific cellular NEP (Figure 1 ,2) and ACE ( Figure 3 ). These substances themselves have, in the short-term (after 1h of incubation), a significant inhibitory effect on the specific cellular NEP activity (Table 1 ). Table 2 shows that the induction effect of NEP and ACE activity is associated with a significant inhibition of cell proliferation (at concentrations of 10-50 µM). The cell proliferation was determined by the DNA assay. On the other hand, the long-term treatment of SK-N-SH cells with amentoflavone (1-20 µM) had no effect on the specific cellular enzyme activity and cellular proliferation ( Figure 2 ). 
Substances 1µM 5µM 10µM 20µM 30µM 50µM
Apigenin 92±10 86±5 40±12* 15±11* 12±13* 10±7* Luteolin 97±11 82±6 30±20* 10±12* 8±10* 5±9* Vinpocetin 100±4 99±6 78±10* 52±9* 39±12* 28±6* *Significant difference to cell proliferation of the controls (p < 0.05).
Effects of apigenin and luteolin on the specific cellular NEP activity with blocked DNA synthesis:
In further experiments we tested the induction effect on the specific NEP activity with blocked DNA synthesis. This was undertaken to refine knowledge about the mode of action. For this purpose we treated the cells with arabinosylcytosine 60 ng/mL in combination with either apigenin or luteolin (10 µM).
Arabinosylcytosine, a selective inhibitor of DNA synthesis, induced, alone, cellular NEP activity (Table 3) connected with a strong inhibition of cell proliferation (10 ± 8%, n = 16). Table 3 shows also that the treatment of the DNA synthesis-blocked cells with apigenin and luteolin (10 µM) led to an additional increase in cellular NEP and ACE induction, which demonstrates that this induction depends not only on the inhibition of cell proliferation.
This result supports our supposition, that apigenin and luteolin influence, directly, the gene expression of NEP via an increase in the intracellular cAMP level. It is known that the elevation of cAMP by forskolin, dibutyryl-cAMP and 8-bromo-cAMP (as positive reference compounds) induced an increase of NEP activity and NEP protein after 24 h of incubation in human endothelial cells [24] . *Significant difference to cell proliferation of the controls (p < 0,05).
The treatment with 60 ng/mL arabinosylcytosine alone strongly enhanced NEP activity and inhibited cell proliferation: 8 ± 8% in comparison to the control without any treatment, n = 16. This value was defined for the combination experiments as control (100%) and any additional inhibition of cell proliferation by apigenin and luteolin treatment was calculated on the base of proliferation inhibition by arabinosylcytosine alone.
In the present study, the treatment of SK-N-SH cells with apigenin, luteolin and vinpocetine led to a significance increase in the cellular enzyme activity of NEP and ACE. A possible explanation for the observed enzyme induction effects might be based on the relation between cellular differentiation and cellular proliferation. The processes of differentiation and proliferation are mutually exclusive. A non-toxic inhibition of cell proliferation enhances, in most cases, the cellular differentiation state. This correlation was observed investigating the differentiating effect of retinoic acid on matrix metalloproteinase-2 (MMP-2) expression; the proliferative activity was inversely correlated to MMP-2 expression in SK-N-SH cells [25] . In the case of NEP, it has been reported that in different cell types the up-regulation of the cellular enzymatic activity is correlated to an enhanced cellular differentiation state, as well as to the inhibition of cellular proliferation [26] . The enhanced cellular enzyme activities are, by that, a proof for the assumption that the inhibition of cell proliferation was not the result of a cytotoxic effect. For ACE the enzyme induction seems to be coupled with the mitogen-activated protein kinase and early growth response 1 transcription factor [27] . In our investigations, the increase of cellular enzyme activity of NEP and ACE was associated with significant inhibition in cellular proliferation, which demonstrates an enhancement of cellular differentiation. Furthermore, we investigated the effect of the combination of arabinosylcytosine, which blocks DNA synthesis, with either apigenin or luteolin (10 µM) on the activity of NEP to exemplify the knowledge about the mode of action. We found that this combination led to an additional increase in cellular NEP induction, demonstrating that the induction by these flavonoids was at least partly independent of the inhibition of cell proliferation. A presumable explanation for the observed enzyme induction effects might be based on the increase of cAMP level enhanced NEP gene expression via transcription factors. It has been reported that activation of adenylate cyclase by either forskolin or prostaglandin E1 induced an increase of NEP activity and NEP protein after 24 h of incubation in human endothelial cells. This effect was mimicked by two activators of protein kinase A, dibutyryl-cAMP and 8-bromo-cAMP [24] .
The cAMP level is a key for protection, growth and myelination of injured CNS axons in vivo and recovery of function [28] . The elevating of cAMP levels is considered as a therapeutic potential for the delay of Alzheimer's disease progression. Alzheimer's disease related increases in the amyloid precursor protein C-terminal derivative can be reversed by treatment with agents that increase intracellular cAMP, such as dibutyryl-cyclic-AMP, theophylline, and isoproterenol [29] . It is known that flavonoids are able to elevate the level of intracellular cAMP by inhibition of phosphodiesterase enzyme (PDE) [15] . Apigenin inhibits PDE1-3 with IC 50 values of around 10-25 µM, whereas luteolin inhibits PDE1-5 with IC 50 values in a range of 10-20 µM [30] . Therefore, we have tested these concentrations of apigenin and luteolin in our study in a cell culture system. Flavonoids are known to inhibit both lipopolysaccharide (LPS) stimulated tumor necrosis factor alpha and interleukin-6 release, which modulate the proinflammatory molecules that have been reported in many progressive neurodegenerative disorders, including Alzheimer's disease (AD), viral and bacterial meningitis, AIDS dementia complex, and stroke. The chronic treatment with flavonoids reverses cognitive deficits in aged and LPSintoxicated mice [31] . In general, flavonoids occur in plants either in the form of aglycones or glycosides. The aglycones are capable of being absorbed freely from the gut by passive diffusion, while the flavonoid glycosides are usually hydrolyzed to the corresponding aglycone prior to its gastrointestinal absorption [32] . Nevertheless, in both aglycone and glycosides, the flavonoid bioavailabilities have not been found as high as expected from their favourable lipophilicity. Such discrepancies are believed to be due mainly to their extensive first-pass metabolic effect in the small intestine [33] . There are no data about the exact concentration of flavonoids in the brain. Vinpocetine is a specific inhibitor of the PDE 1 isoform. This effect would theoretically lead to an increase of cyclic AMP and cyclic GMP and may be responsible for the benefits in cerebral circulation and decreasing the platelet aggregation observed after vinpocetine administration [34] . Vinpocetine, with an IC 50 value of 30 µM, inhibits PDE1 and increases cAMP concentration in guinea pig Taenia coli, producing relaxation of the muscle [35] . Vinpocetine has been shown to be efficient in protecting neurons from the toxicity of glutamate and N-methyl-daspartate and it is known to be a powerful antioxidant [36] . The main mechanism involved in the neuroprotective action of vinpocetine in the CNS is unlikely to be due to a direct inhibition of either Ca 2 + channels or PDE enzymes, but rather the inhibition of presynaptic Na+ channel-activation unchained responses [37] . Vinpocetine reaches the bloodstream approximately one hour after administration, whether taken with food or on an empty stomach [38] and it has an absorption rate of 6.7% without food and 60-100% with food [39] . Recent studies, either following i.v. infusion of vinpocetine in patients with cerebrovascular disorders or using positron emission tomography (PET) scans in animals, have shown that vinpocetine crosses the blood-brain barrier and is taken up by cerebral tissue [40] . Also, PET studies have clearly shown that in human subjects vinpocetine is preferentially absorbed in the central nervous system at twice the rate that would be expected according to total body distribution. The highest uptake of vinpocetine was seen in the thalamus, putamen, and neocortical regions [41] . Therefore, from our study, the enhancement effect of vinpocetine on the specific cellular enzyme activity of NEP and ACE in vitro can be useful in the degradation of ?-amyloid peptides (A?) and prevent the accumulation of amyloid plaques in vivo. We
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have also found that apigenin and luteolin are able to induce the up-regulation of NEP and ACE by inhibition of cell proliferation in a non-toxic manner and by that they act as cell differentiation enhancing compounds. They are also able to enhance the NEP and ACE expression possibly via increasing the intracellular cAMP level.
Finally, based on the results presented in this study, it seems that the increase of the cellular activity of NEP and ACE by apigenin, luteolin and vinpocetine not only depends on the differentiation improvement, but also by direct influence on the gene expression of NEP and ACE as well. From this point of view the up-regulation of NEP and ACE by these substances can be described as neuroprotective effects, combined with an enhanced degradation of β-amyloid peptides (Aβ), which may affect the susceptibility to AD and prevent the accumulation of amyloid plaques in vivo.
Experimental

Chemicals and test compounds:
Succinyl-L-Ala-L-Ala-L-Phe-7-amido-3-methylcoumarin (SAAP-AMC), aminopeptidase N (APN), arabinosylcytosine and phosphoramidon were obtained from Sigma. Hip-L-His-L-Leu was purchased from Bachem; lisinopril was a gift of Schering and Plough. The cell culture media and fetal calf serum (FCS) were obtained from Biochrom. Hoechst 33258 was obtained from Sigma. A stock solution of Hoechst 33258 was made (1 mg/mL) in distilled deionized water and stored foil-wrapped at 4°C. Apigenin, luteolin and vinpocetin were obtained from Sigma, and amentoflavone from Roth.
Cell culture: SK-N-SH cells, and human neuroblastoma cells were obtained from American Type Culture Collection (ATCC) (No. HTB-11) and cultivated in Minimal Essential Medium (MEM with Earls salts) with sodium pyruvate and non-essential amino acids plus 10% fetal calf serum at 37°C in a humidified atmosphere with 5% CO 2 according to ATCC instruction manual (Rockville, USA). Subcultivation was performed in 70 cm² culture flasks until confluence and then cells were seeded for the enzymatic experiments in 24-well plates. For the long-term experiments the cells were incubated with the indicated concentration of the test compound 24 h after plating and cultivated for a further 3 to 4 days. Then the medium was removed and replaced by NEP-assay solution.
NEP activity: Determination of the specific NEP activity was performed according to Bormann and Melzig [42] . Briefly, 50 µL of SAAP-AMC-solution (50 µM) and 400 µL of HEPES-buffer (50 mM + 154 mM NaCl, pH 7,4) were added to the intact cell layer after removing the growth medium. To investigate the acute inhibitory activity of a test substance, this compound was simultaneously added. The cells with assay solution were incubated for 60 min at 37°C. The NEP reaction was stopped by adding 50 µL phosphoramidon (50 µM). The incubation mixture (400 µL) from each well was transferred to an Eppendorf tube and 20 µL of an APN-solution (1:235 diluted with water) was added, and the reaction mixture was incubated again for 60 min at 56°C. Adding 800 µL acetone terminated the reaction. The fluorescence of the released AMC was measured at λexit =367 nm, λemiss = 440 nm and slit = 3nm. To calculate the enzyme activity, a calibration curve with AMC was determined.
ACE activity:
The assay was performed according to Bormann and Melzig [42] . Briefly, 20 µL of Hip-L-His-L-Leu solution (24 mM in water) and 260 µL of phosphate-buffer (83 mM K 2 HPO 4 X 3 H 2 O + 326 mM NaCl, pH 8,3) were added to the intact cell layer after removing the growth medium. To investigate the acute inhibitory activity of a test substance this compound was simultaneously added. The cells with assay solution were incubated for 20 min at 37°C. The incubation mixture of each well (250 µL) was transferred to an Eppendorf tube and the reaction was stopped by the addition of 1 mL 0.4 N NaOH, plus 100 µL o-phthalaldehyde solution (2 % in methanol, freshly prepared). Under exclusion of light this mixture was incubated for 10 min at room temperature. Adding 300 µL 2 N HCl terminated the reaction. The fluorescence of the formed product was measured at λexit =360 nm, λemiss =500 nm and slit =3nm. To calculate the enzyme activity, a calibration curve with L-His-L-Leu was determined. During the enzymatic reaction and considering the absorbance of fluorescent light by test compounds, the inhibition rates were calculated in comparison to controls without an inhibitor. Enzyme activity was calculated in pmol/min per 100,000 cells for ACE and NEP. In all investigations the effect of DMSO was considered in separate control experiments.
DNA Assay:
The assay was performed in 24-well plates using Hoechst 33258 reagent after cell lysis by freezing in distilled deionized water [43, 44] . After determination of NEP activity, the 24-well plates were washed with saline solution (0,9% NaCl). By the same manner and after removing the salinesolution, 400 µl of distilled water was added. The plates were frozen at -20°C. On the day of assay the plates were thawed until reaching room temperature and then the plates were frozen again for 1 h. The plates were thawed until reaching room temperature. Next, 400 µL of DNA-buffer (41 mM Na 2 HPO 4 * 12H 2 O + 9 mM NaH 2 PO 4 * H 2 O + 2M NaCl + 2 mM EDTA, pH 7,4) was added to each well. 740 µL of the mixture of each well was transferred in an Eppendorf tube, and 60 µl of Hoechst 33258 (10 µL of the stock solution + 1 mL water) was added. The fluorescence of the formed product was measured (at λexit =356 nm, λemiss = 458 nm, slit 5 nm). A calibration curve with DNA was determined to calculate the amount of DNA in each well.
Cell counting:
The cells were dissociated with trypsin/EDTA (0.25% /0.02%) and counted with the cell analyzer system CASY (SCHÄFER System, Germany). The values of the cell numbers represent the mean of at least three independent experiments with two parallel samples.
Statistics:
The assays were performed in at least three independent experiments with four parallel samples. All values in the table and figure are expressed as mean ± standard error. During enzyme reaction, the inhibition rates were calculated as a percentage relative to controls without inhibitors. Wilcoxon's U-test was used to test significance (p< 0.05).
